India Business Law Journal Names Cravath Among Key Players of 2024 for India‑Related Work
July 19, 2024
On July 17, 2024, the India Business Law Journal named Cravath among the “Key Players” in its 2024 ranking of the leading foreign law firms involved in India‑related work. The publication noted that Cravath “is often appointed on complex, high‑value deals involving Indian parties” and highlighted its representation of Tata Technologies Limited in its IPO, as well as Viatris in the divestitures of its Women’s Healthcare business and Active Pharmaceutical Ingredient business in India. Interviewees said the Firm is “proactive in covering matters and anticipating the next steps” and has “offered excellent services,” highlighting the work of Cravath partner Philip J. Boeckman.
Related Practices & Industries
People
- Photo
-
-
J.D., 1991, University of Missouri Columbia School of LawOrder of the Coif, magna cum laude
-
B.A., 1988, Westminster Collegecum laude
- New York
Education
Admitted In
Related News
Deals & Cases
December 05, 2023
Tata Technologies Limited’s IPO
Cravath represented Tata Technologies Limited as international counsel in connection with its INR 30.4 billion 144A/Reg. S initial public offering of equity shares. Tata Technologies Limited is a leading global engineering services company offering product development and digital solutions, including turnkey solutions, to global original equipment manufacturers and their Tier 1 suppliers globally. The shares began trading on the Bombay Stock Exchange and the National Stock Exchange of India on November 30, 2023.
Deals & Cases
October 02, 2023
Viatris’s $6.94 Billion in Announced Divestitures
On October 1, 2023, Viatris Inc. (“Viatris”), a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (“OTC”) business, and has entered into definitive agreements to divest its Women’s Healthcare business, its Active Pharmaceutical Ingredient (“API”) business in India and commercialization rights in certain non-core markets that were acquired as part of the combination with Upjohn. The total transactions value, including Viatris’s 2022 divestiture of its biosimilars business, represents up to $6.94 billion of total gross proceeds. The estimated transaction value for the divestitures announced today is $3.6 billion, including gross consideration of up to approximately $2.17 billion for the divestiture of substantially all of its OTC business, and up to approximately $1.2 billion combined for the divestitures of its API and Women’s Healthcare businesses. Cravath is representing Viatris in connection with the transactions.
